Fibre Extrusion Technology (FET), a UK-based specialist extrusion equipment exporter for textile, medical and composite sectors, has delivered its ninth meltspinning systems in the biomedical sector since the onset of COVID-19. This confirms FET’s position as a world leader in meltspinning equipment for precursor materials used in medical devices, according to the company.
“FET has a long tradition in the highly regulated biomedical sector and we believe our experience is unrivalled. We have built a world leading reputation for melt spinning medical grade polymers in both synthetic resorbable and non-absorbable polymers and FET is now reaping the rewards of this initiative,” Richard Slack, managing director at FET, said in a press release.
“Recent installations include a multi-functional system that can produce both multifilament and monofilament pre-cursor fibres, but nonwoven systems have been particularly prominent, driven by the burgeoning demand for FFP3 masks, gowns and other medical products required during the pandemic,” the industrial equipment supplier added. “These have been sold to medical device manufacturing companies across the globe, including the Far East, USA and Europe. Research organisations have also invested in FET systems for biomedical applications, the most recent being the University of Leeds in a laboratory scale Spunbond system.”
The FET in-house process development laboratory and ongoing collaboration with biomaterial polymer suppliers has helped to optimise the biomedical melt spinning technology. This laboratory is at the disposal of customers for all aspects of confidential testing and evaluation. To further increase this competitive edge, FET will be opening a new process development laboratory and visitor centre in early 2022, FET mentioned.
Fibre2Fashion News Desk (JL)